$100.55
0.81%
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US15102K1007
Symbol
CELC

Celcuity Inc. Stock price

$100.55
+3.05 3.13% 1M
+87.51 671.09% 6M
+0.81 0.81% YTD
+87.42 665.80% 1Y
+86.54 617.70% 3Y
+90.12 864.05% 5Y
+86.26 603.64% 10Y
+86.26 603.64% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.81 0.81%
ISIN
US15102K1007
Symbol
CELC
Industry

Key metrics

Basic
Market capitalization
$4.7b
Enterprise Value
$4.5b
Net debt
positive
Cash
$455.0m
Shares outstanding
43.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
39.8
Financial Health
Equity Ratio
47.2%
Return on Equity
-96.7%
ROCE
-36.5%
ROIC
-
Debt/Equity
2.7
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-159.3m | $-169.2m
EBIT
$-159.4m | $-173.3m
Net Income
$-162.7m | $-165.0m
Free Cash Flow
$-144.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-65.7% | -49.6%
EBIT
-65.7% | -53.0%
Net Income
-72.3% | -47.6%
Free Cash Flow
-93.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.4
FCF per Share
$-3.3
Short interest
17.6%
Employees
87
Rev per Employee
$0.0
Show more

Is Celcuity Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Celcuity Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Celcuity Inc. forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a Celcuity Inc. forecast:

Buy
88%
Hold
13%

Financial data from Celcuity Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
140% 140%
-
- Research and Development Expense 141 141
59% 59%
-
-159 -159
66% 66%
-
- Depreciation and Amortization 0.16 0.16
33% 33%
-
EBIT (Operating Income) EBIT -159 -159
66% 66%
-
Net Profit -163 -163
72% 72%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celcuity Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celcuity Inc. Stock News

Positive
Seeking Alpha
10 days ago
Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million...
Neutral
GlobeNewsWire
23 days ago
MINNEAPOLIS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated results from the randomized, Phase 3 VIKTORIA-1 trial for gedatolisib, a multi-target PI3K/AKT/mTOR (“PAM”) inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor r...
Positive
MarketBeat
about one month ago
Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that have posted impressive gains this year.
More Celcuity Inc. News

Company Profile

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Head office United States
CEO Brian Sullivan
Employees 87
Founded 2012
Website www.celcuity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today